Format

Send to

Choose Destination
Cancer Discov. 2016 Oct;6(10):1084-1086.

Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer.

Author information

1
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
2
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. christine.lovly@vanderbilt.edu.

Abstract

In the setting of recent exciting clinical results and numerous ongoing trials, Gainor and colleagues explored mechanisms of acquired resistance to first- and second-generation ALK inhibitors in ALK-rearranged non-small cell lung cancer and found that an increased frequency and distinct spectrums of resistance mutations emerged with the more potent second-generation inhibitors. Their findings have important and immediate clinical implications as the resistance mutations detected impart differential sensitivities to available ALK inhibitors, thereby highlighting the need for sequential biopsies with molecular testing to determine the most effective treatment strategy upon disease progression. Cancer Discov; 6(10); 1084-6. ©2016 AACRSee related article by Gainor et al., p. 1118.

PMID:
27698100
PMCID:
PMC5117458
DOI:
10.1158/2159-8290.CD-16-0910
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center